Developments in cellular and genetic therapies force reevaluation of reimbursement process


As new cellular and genetic therapies are attracting interest in regenerative medicine, payers are struggling to stave off large upfront costs. Read more as Jeremy Schafer shares results gleaned from a Precision for Value survey based on payer market research on gene therapies.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.